These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. PCR-based haplotype determination to distinguish CYP2B6*1/*7 and *5/*6. Futatsugawa Y; Kubota T; Ishiguro A; Suzuki H; Ishikawa H; Iga T Clin Chem; 2004 Aug; 50(8):1472-3. PubMed ID: 15277362 [No Abstract] [Full Text] [Related]
27. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility. Yuan ZH; Liu Q; Zhang Y; Liu HX; Zhao J; Zhu P Ann Hematol; 2011 Mar; 90(3):293-9. PubMed ID: 20878158 [TBL] [Abstract][Full Text] [Related]
28. Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility. Berköz M; Yalin S Leuk Res; 2009 Jul; 33(7):919-23. PubMed ID: 19144407 [TBL] [Abstract][Full Text] [Related]
29. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333 [TBL] [Abstract][Full Text] [Related]
30. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Chang TK; Bandiera SM; Chen J Drug Metab Dispos; 2003 Jan; 31(1):7-10. PubMed ID: 12485946 [TBL] [Abstract][Full Text] [Related]
31. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156 [TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of CYP2B6 cDNA in cynomolgus macaques (Macaca fascicularis). Uno Y; Matsuno K; Nakamura C; Utoh M; Yamazaki H J Vet Med Sci; 2009 Dec; 71(12):1653-6. PubMed ID: 20046035 [TBL] [Abstract][Full Text] [Related]
33. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. Szumlanski C; Otterness D; Her C; Lee D; Brandriff B; Kelsell D; Spurr N; Lennard L; Wieben E; Weinshilboum R DNA Cell Biol; 1996 Jan; 15(1):17-30. PubMed ID: 8561894 [TBL] [Abstract][Full Text] [Related]
34. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205 [TBL] [Abstract][Full Text] [Related]
35. Characterization of human CYP2G genes: widespread loss-of-function mutations and genetic polymorphism. Sheng J; Guo J; Hua Z; Caggana M; Ding X Pharmacogenetics; 2000 Nov; 10(8):667-78. PubMed ID: 11186129 [TBL] [Abstract][Full Text] [Related]
36. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275 [TBL] [Abstract][Full Text] [Related]
37. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352 [TBL] [Abstract][Full Text] [Related]
38. Pyrosequencing-based screening for the genetic polymorphism CYP2B6 1459 C > T. Doehring A; Lötsch J Pharmacogenomics; 2009 Oct; 10(10):1577-9. PubMed ID: 19842930 [No Abstract] [Full Text] [Related]
40. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4. Casabar RC; Wallace AD; Hodgson E; Rose RL Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]